The FDA has approved Sevenfact (coagulation factor VIIa [recombinant]-jncw; LFB Biotechnologies) for the treatment and control of bleeding episodes occurring in patients aged ≥12 years with hemophilia A or B with inhibitors.
Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII). It is a rare disorder that can be complex to diagnose and manage. The World Federation of Hemophilia published guidelines in 2012 outlining optimal treatment strategies and recent research has highlighted emerging drugs to treat patients with hemophilia…
Please login or register first to view this content.
